References
- Richard P, Gutmann L. Sparfloxacin and other new fluoroquinolones. J Antimicrob Chemother 1992; 30: 739–744.
- Paganoni R, Herzog C, Braunsteiner A, Hohl P. Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin. J Antimicrob Chemother 1988; 22 (suppl.) D: 3–17.
- Nightingale CH. Overview of the pharmacokinetics of fleroxacin. Am J Med 1993; 94 (suppl.) 3A: S38-S43.
- National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A2 1990 (second edition). National Committee for Clinical Laboratory Standards, Villanova, PA.
- Verschraegen G, Claeys G, Van-den-Adeele AM. Comparative in vitro activity of the new quinolone fleroxacin (Ro 23- 6240). Eur J Clin Microbiol Infect Dis 1988; 7: 63–66.
- Barry AL, Fuchs PC. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob Agents Chemother 1991; 35: 955–960.
- Maple PAC, Hamilton-Miller JMT, Brumfitt W. Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1991; 35: 345–350.
- Schaefler S. Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones. J Clin Microbiol 1989; 27: 335–336.
- Legakis NJ, Tzouvelekis LS, Tsakris A, Legakis JN, Vatopoulos AC. On the incidence of antibiotic resistance among gram-negative rods isolated in Greek hospitals. J Hosp Infect 1993; 24: 233–237.